Crinetics Pharmaceuticals (NASDAQ:CRNX) (NASDAQ: CRNX) is a clinical‐stage biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule therapeutics for rare endocrine diseases and endocrine‐related tumors. The company’s research and development efforts are focused on addressing disorders driven by peptide hormone excess or hormone receptor dysregulation, leveraging proprietary chemistry and structure‐based design to develop oral, nonpeptide compounds with the potential to improve patient outcomes and quality of life.
At the core of Crinetics’ pipeline is paltusotine (CRN00808), an oral somatostatin receptor type 2 (SST2) agonist in later‐stage clinical studies for the treatment of acromegaly. The company is also advancing CRN04777, an ACTH receptor antagonist for congenital adrenal hyperplasia, and CRN04894, an ACTH antagonist candidate targeting Cushing’s disease as well as adrenal tumors. Additional discovery programs are exploring treatments for pheochromocytoma, paraganglioma and other endocrine tumors, reflecting Crinetics’ commitment to addressing a broad spectrum of unmet needs in endocrinology.
Founded in 2013 and headquartered in San Diego, California, Crinetics has built a multidisciplinary team of drug discovery scientists, clinical developers and regulatory experts. The company conducts early‐stage research at its U.S. facilities while engaging with academic and clinical partners in North America, Europe and Asia to support global development plans. Since completing its initial public offering in 2019, Crinetics has continued to strengthen its manufacturing capabilities and prepare for potential commercialization across multiple territories.
Under the leadership of Founder and Chief Executive Officer Jai Patel, Ph.D., Crinetics has attracted seasoned executives and board members with deep experience in endocrinology and rare disease drug development. The company’s management team is supported by external advisors and strategic collaborations aimed at optimizing trial design, regulatory strategy and long‐term access. As Crinetics advances its lead candidates toward pivotal studies, its goal remains to bring first‐in‐class and best‐in‐class therapies to patients living with rare endocrine disorders.
